JP2023549555A5 - - Google Patents

Info

Publication number
JP2023549555A5
JP2023549555A5 JP2023529918A JP2023529918A JP2023549555A5 JP 2023549555 A5 JP2023549555 A5 JP 2023549555A5 JP 2023529918 A JP2023529918 A JP 2023529918A JP 2023529918 A JP2023529918 A JP 2023529918A JP 2023549555 A5 JP2023549555 A5 JP 2023549555A5
Authority
JP
Japan
Prior art keywords
cdr
sequence
seq
isolated antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023529918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549555A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/059955 external-priority patent/WO2022109178A1/en
Publication of JP2023549555A publication Critical patent/JP2023549555A/ja
Publication of JP2023549555A5 publication Critical patent/JP2023549555A5/ja
Pending legal-status Critical Current

Links

JP2023529918A 2020-11-18 2021-11-18 抗marco抗体及びその使用 Pending JP2023549555A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063115272P 2020-11-18 2020-11-18
US63/115,272 2020-11-18
US202163244662P 2021-09-15 2021-09-15
US63/244,662 2021-09-15
PCT/US2021/059955 WO2022109178A1 (en) 2020-11-18 2021-11-18 Anti-marco antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2023549555A JP2023549555A (ja) 2023-11-27
JP2023549555A5 true JP2023549555A5 (cg-RX-API-DMAC7.html) 2024-11-20

Family

ID=81588283

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023529918A Pending JP2023549555A (ja) 2020-11-18 2021-11-18 抗marco抗体及びその使用

Country Status (10)

Country Link
US (3) US11572407B2 (cg-RX-API-DMAC7.html)
EP (1) EP4247419A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023549555A (cg-RX-API-DMAC7.html)
KR (1) KR20230121759A (cg-RX-API-DMAC7.html)
AU (1) AU2021382658A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198579A1 (cg-RX-API-DMAC7.html)
IL (1) IL302874A (cg-RX-API-DMAC7.html)
MX (1) MX2023005841A (cg-RX-API-DMAC7.html)
TW (1) TW202237648A (cg-RX-API-DMAC7.html)
WO (1) WO2022109178A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237648A (zh) 2020-11-18 2022-10-01 美商開拓免疫醫療公司 抗marco抗體及其用途
US20250011410A1 (en) * 2021-11-23 2025-01-09 Invetx, Inc. Anti-ngf antibodies and uses thereof
US20260008844A1 (en) * 2022-09-15 2026-01-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Use of anti-marco antibody with a checkpoint blockade antibody for the treatment of cancer
US20260126450A1 (en) * 2022-10-12 2026-05-07 Massachusetts Institute Of Technology Library-scale methods for polypeptide functional analysis
WO2025102054A1 (en) * 2023-11-09 2025-05-15 Massachusetts Institute Of Technology Methods of screening for secreted functional molecules

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916766A (en) 1996-05-23 1999-06-29 Smithkline Beecham Corporation Human marco scavenger receptor
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US20100227415A1 (en) 2007-07-24 2010-09-09 Iss Immune System Stimulation Ab Method and means for prediction of systemic lupus erythematosus susceptibility
US8597946B2 (en) 2008-03-10 2013-12-03 H. Lee Moffitt Caner Center and Research Institute, Inc. Enhanced dendritic cells for cancer immunotherapy
KR20130108295A (ko) * 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
WO2012122396A1 (en) 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
WO2016196612A1 (en) 2015-06-01 2016-12-08 The Rockefeller University Anti-tumor agents and methods of use
WO2017062363A1 (en) 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
EP3612563A1 (en) 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
TW201904588A (zh) 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
EP3668899A4 (en) 2017-08-18 2020-09-02 Celdara Medical, LLC CELL-BASED THERAPIES TARGETING DISEASE-ASSOCIATED MOLECULAR MEDIATORS OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE DISEASES
PL3688155T3 (pl) 2017-09-28 2023-09-11 Immpact-Bio Ltd. Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
MX2020006654A (es) 2017-12-22 2020-11-06 Atossa Therapeutics Inc Métodos intraductales de tratamiento de trastornos de mama.
MX387358B (es) 2018-02-28 2025-03-18 Pfizer Variantes de il-15 y usos de las mismas
BR112021006100A2 (pt) 2018-09-28 2021-07-20 Immpact-Bio Ltd. métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
JP2022514215A (ja) * 2018-12-05 2022-02-10 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ Rankアンタゴニストおよびその使用
EP3906055A4 (en) 2019-01-04 2023-01-04 Trio Pharmaceuticals, Inc. MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES
WO2020162696A1 (ko) 2019-02-08 2020-08-13 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
US20220152148A1 (en) 2019-03-18 2022-05-19 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
IL287801A (en) 2019-05-07 2022-07-01 Immunicom Inc Increasing responses to checkpoint inhibitors by extracorporeal apheresis
GB2603044B (en) 2019-06-11 2024-08-21 Myeloid Therapeutics Inc Macrophage specific engager compositions and methods of use thereof
KR20220054305A (ko) 2019-07-31 2022-05-02 온코어 파마, 인크. 면역 회피성 종양의 치료
TW202237648A (zh) 2020-11-18 2022-10-01 美商開拓免疫醫療公司 抗marco抗體及其用途

Similar Documents

Publication Publication Date Title
TWI769537B (zh) 標靶bcma的抗體、雙專一性抗體及其用途
JP2021506244A5 (cg-RX-API-DMAC7.html)
JP2022514734A5 (cg-RX-API-DMAC7.html)
CN110431231B (zh) 抗-cd3抗体和包含所述抗体的分子
JP7649744B2 (ja) Btn3a結合タンパク質及びその使用
CN106519034B (zh) 抗pd-1抗体及其用途
JP2021508469A5 (cg-RX-API-DMAC7.html)
JP2024056687A5 (cg-RX-API-DMAC7.html)
TW201833141A (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
RU2017122014A (ru) Антитела к c10orf54 и их применения
JP2021520832A5 (cg-RX-API-DMAC7.html)
JP2024001073A5 (cg-RX-API-DMAC7.html)
JP2022523145A5 (cg-RX-API-DMAC7.html)
JP2025501206A (ja) Gprc5d抗体及びその応用
WO2022002033A1 (zh) 具有H2L2与HCAb结构的结合蛋白
CN113574069A (zh) 抗pd-l1抗体及其用途
IL312060A (en) Bispecific CD16A binders
JP2022540610A5 (cg-RX-API-DMAC7.html)
JP2023547662A5 (cg-RX-API-DMAC7.html)
RU2010122044A (ru) УЛУЧШЕННЫЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Nogo-А И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
CA3160765A1 (en) Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
WO2023125289A1 (zh) 抗pd-1抗体及其用途
JP2025509702A (ja) GPC3陽性悪性細胞を標的殺傷するための二重特異性GPC3xCD28抗体およびGPC3xCD3抗体ならびにそれらの組み合わせ
KR20250122463A (ko) 항체 및 이의 용도
IL323042A (en) Anti-dog PD-L1 antibodies